Abstract Background/purpose: The purpose of this study is to describe clinical characteristics of Salmonella bacteremia in adult patients and analyze ciprofloxacin-nonsusceptible isolates. Methods: A total of 101 Salmonella blood isolates from adult patients were collected from January 2011 to December 2013 in MacKay Memorial Hospital. Eight ciprofloxacinnonsusceptible Salmonella blood isolates were screened for carbapenemase and other b lactamase genes. Isolates were examined by PCR for the quinolone resistance-determining region (QRDR) of all subunits for DNA gyrase (gyrA and gyrB) genes and topoisomerase IV (parC and parE ) genes. Results: There were 22 (21.78%) S. enterica serovar B, 5 (4.95%) S. enterica serovar C 1 , 7 (6.93%) S. enterica serovar C 2, 65 (64.36%) S. enterica serovar D, and 2 (1.98%) S. enterica serovar Typhi (S. typhi) isolates. b-lactamase gene screening and sequencing yielded only one bla CMY-2 -positive isolate. In multivariate risk factor analysis, renal insufficiency [odds ratio (OR) 3.774; p Z 0.020] and heart disease (OR 2.922; p Z 0.027) were more common among elderly patients (!65 years). Independent risk factors for ciprofloxacin-nonsusceptible strains included S. enterica serovar C 2 (OR 28.430; p Z 0.032), renal insufficiency (OR 13.927; p Z 0.032), and immunosuppression agent usage (OR 60.082; p Z 0.006). 87.50% (7/8) of isolates had gyrA mutation, 62.50% (5/8) had parC mutation, and none had gyrB and parE mutations. Isolates with both Ser83Phe/Asp87Asn gyrA and Thr57Ser/Ser80Ile parC mutation genes were highly ciprofloxacin-resistant (minimum inhibitory concentration !4 mg/L). Conclusions: Elderly patients with renal insufficiency and heart disease were at risk for Salmonella bacteremia. Those for ciprofloxacin-nonsusceptible strains included S. enterica serovar C 2 , renal insufficiency, and immunosuppression agent usage. The 8 ciprofloxacinnonsusceptible isolates carried gyrA and parC mutations, which cause resistance that poses a major concern.
Introduction
Salmonella infection is an important public health problem worldwide. The burden is significant, with an estimated 93.8 million cases globally and 155,000 deaths each year. 1, 2 The average number of annual incidences of bacteremia due to Salmonella species is 103 cases per million inhabitants in southern Taiwan. 3 Salmonella bacteremia is usually identified by the following serogroups in microbiological laboratories: S. enterica serovar B, S. enterica serovar C 1 , S. enterica serovar C 2 , S. enterica serovar D, and S. enterica serovar Typhi. 4 Lee et al 5 revealed that bacteremia due to nontyphoidal Salmonella presented with different clinical features in adults than it did in children. Nontyphoidal Salmonella bacteremia in children rarely caused fatalities, whereas it should be considered life-threatening in adult patients, regardless of primary or secondary bacteremia. 6 Salmonella bacteremia has important clinical significance because it affects patients who usually have underlying diseases, such as an immunocompromised status, connective tissue diseases, use of therapeutic immunosuppressants, systemic lupus erythematosus, malignancies, diabetes mellitus, and human immunodeficiency virus infection.
5À9
When an invasive or severe Salmonella infection is encountered, ceftriaxone is recommended. 10 Much evidence indicates that the resistance to third-generation cephalosporins poses a major concern for use as an empiric antimicrobial therapy for Salmonella infection. 10À12 DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE ) are the principal targets for antibacterial activity of quinolones. One mechanism that has been widely reported and associated with ciprofloxacin-resistance is mutations in target genes in the quinolone resistancedetermining region (QRDR). Mutations at codon Ser83 or Asp87 are known to be common sites of mutation in gyrA, resulting in quinolone resistance. The gyrA mutations could be detected as Ser83Phe, Ser83Tyr, and Asp87Asn, while parC mutations are detected as Thr57Ser and Ser80Ile.
13À15
The risk factors of Salmonella bacteremia have been reported around the world in recent years. 5, 6, 7, 16 However, there are currently only a few articles reporting information concerning elderly patients and ciprofloxacinnonsusceptible strains with Salmonella bacteremia. The purpose of this study is to describe the clinical characteristics of adult patients with Salmonella bacteremia and to analyze the ciprofloxacin-nonsusceptible isolates.
Methods
Bacterial isolate collection, ciprofloxacin and ceftriaxone susceptibility testing, and patient characteristics
The 101 Salmonella blood isolates from patients aged !18 years were collected from January 2011 to December 2013 in MacKay Memorial Hospital, a 2200-bed hospital in Taiwan. For patients with !2 positive blood cultures, only the first isolate was included. Identification was performed using the Vitek 2 system (bioMérieux Vitek Systems Inc., Hazelwood, MO, USA). O antisera was determined by the slide agglutination test by Difco antisera (Becton Dickinson, MD, USA) and used to identify the S. enterica isolates as serogroups A, B, C 1 , C 2 , D, and Typhi. Susceptibility tests for ciprofloxacin and ceftriaxone were also performed using the Vitek 2 system. Isolates were kept frozen at À70 C in trypticase soy broth (Becton Dickinson) containing 20% glycerol (v/v) until further testing. In addition, antibiotics susceptibilities against ciprofloxacin was also determined by the agar dilution method. The minimum inhibitory concentrations (MICs) of ciprofloxacin and ceftriaxone were interpreted according to the Clinical and Laboratory Standards Institute guidelines. 17, 18 Medical records were reviewed, and the following data were collected: patient characteristics, comorbidities, invasive procedure use (Table 1) , and whether or not the patient was in the intensive care unit (ICU) at the time of bacteremia onset. Central line-associated infection was defined according to the United States Centers for Disease Control and Prevention guidelines. 19 Liver cirrhosis was diagnosed by gastroenterologists based on laboratory and radiological evidence. Renal insufficiency was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73 m 2 . Attributable mortality indicated that a patient died during the admission period of a Salmonella bacteremia episode. This study was approved by the MacKay Memorial Institutional Review Board with protocol number 14MMHIS131.
Pulse-field gel electrophoresis
The eight ciprofloxacin-nonsusceptible Salmonella isolates were identified by pulse-field gel electrophoresis (PFGE) following the digestion of intact genomic DNA with XbaI (Biolabs, Beverly, MA, USA). The DNA fragments were separated on 1% (w/v) SeaKem GTG agarose gels in 0.5% TBE [Tris-borate ethylene diamine tetra-acetic acid (EDTA)] buffer. This was done in a CHEF Mapper apparatus (Bio-Rad, Hercules, CA, USA) with a potential of 6 V/cm pulsed from 2.16 seconds to 63.8 seconds for 19 hours at 14 C. 20 The completed gels were stained with ethidium bromide and photographed with ultraviolet light.
The XbaI restriction profiles were initially compared to each other by visual inspection, and isolates were considered to be closely related if they showed differences of less than three bands. 21 Computer-assisted analysis was also performed using BioNumerics (Applied Maths, Sint-MartensLatem, Belgium). Cluster analysis was performed by the unweighted pair group method with mathematical averaging, and DNA relatedness was calculated using the bandbased Dice coefficient with 1.0% band tolerance and a 1.56% optimization setting for the whole profile. Isolates were considered to belong to the same cluster when the similarity coefficient reached 85%.
Polymerase chain reaction (PCR) and sequencing
The eight ciprofloxacin-nonsusceptible Salmonella blood isolates were examined by PCR for QRDR of all subunits for DNA gyrase (gyrA and gyrB) genes and topoisomerase IV (parC and parE ) genes using published primers. 13, 15 The PCR preparation procedure is outlined as follows. Bacteria were boiled in sterile water for 10 minutes, and the supernatant was collected and used as DNA sources for PCR. The 25 mL reaction mixture consisted of 1X S-T Gold buffer, 1.5mM MgCl 2 , 0.2mM deoxynucleotides (dNTP), and 20 pmol of each primer. The PCR amplicons were purified Table 1 Demographic and clinical characteristics according to variables of age and ciprofloxacin susceptibility among 101 patients with Salmonella enterica bacteremia. a Data are presented as mean AE standard deviation for age. CIP-ns Z ciprofloxacin-nonsusceptible; COPD Z chronic obstructive pulmonary disease; CRO-r Z ceftriaxone-resistant; CVA Z cerebrovascular accident; CVC Z central venous catheter; DM Z diabetes mellitus; ICU Z intensive care unit; Serovar B Z Salmonella enterica serovar B; Serovar C 1 Z Salmonella enterica serovar C 1 ; Serovar C 2 Z Salmonella enterica serovar C 2 ; Serovar D Z Salmonella enterica serovar D; Serovar Typhi Z Salmonella enterica serovar Typhi;
Demographic and clinical characteristics n (%)
using ExoSAP-IT reagent (USB Corporation, Cleveland, OH, USA), and both strands were sequenced using the standard dideoxynucleotide method in an ABI Prism 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA). Sequence similarity searches were performed with the basic local alignment search tool (BLAST; http://blast.ncbi. nlm.nih.gov/Blast.cgi).
Scoring algorithm for predicting vascular infections
Chen et al 22 designed a simple scoring algorithm for predicting vascular infections with nontyphoidal Salmonella bacteremia. In this scoring system, male sex, hypertension, coronary arterial disease, and S. enterica serovar C 1 infections are each assigned þ1 point to form the nontyphoidal Salmonella vascular infection score. In contrast, malignancy and immunosuppressive therapy are each assigned À1 point owing to their negative associations with vascular infections. A cutoff value of þ1 represents a high sensitivity (95.0%) and an acceptable specificity (45.3%). 22 We reviewed the medical record and imaging report such as computer tomography to find out the patient gets vascular infection or not.
Statistical analysis
Categorical variables were described as numbers and percentages. The age variable is presented as a mean value with standard deviation (SD). Categorical variables were analyzed using the Chi-square test with Yates' continuity correction or Fisher's exact test as appropriate. Continuous variables were analyzed by the Student two-sample t test for parametric methods. Logistic regression models were used to identify independent risk factors. Odds ratios (OR) and 95% confidence intervals (CI) were analyzed separately for each of the risk factor variables by the univariate analysis. Subsequently, all significant variables with p 0.05 in the univariate analysis were used in the multivariate analysis of the logistic regression model. All data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 21.0 (SPSS Inc., Chicago, IL, USA).
Results
To describe patient characteristics, comorbidities, invasive procedure use, and serogroups of isolates, a total of 101 Salmonella blood isolates were collected during the study period. There were 22 (21.78%) S. enterica serovar B, 5 (4.95%) S. enterica serovar C 1 , 7 (6.93%) S. enterica serovar C 2, 65 (64.36%) S. enterica serovar D, and 2 (1.98%) S. enterica serovar Typhi (S. typhi) isolates.
The age distribution of the study population was 62.81 AE 18.65 years. The male-to-female ratio was 64:37 (males, 63.37%, 64/101). There were 49 patients aged !65 years. Table 1 shows the demographic and clinical characteristics according to variables of age and ciprofloxacin susceptibility among 101 adult patients with Salmonella enterica bacteremia. The mean (AE SD) age of adult patients <65 years old was 48.29 AE 13.627 years. The mean (AE SD) age of elderly patients !65 years old was 78.22 AE 7.504 years. Compared with the <65-year-old adult patients, more patients older than 65 had heart disease (40.82% vs. 19.23%; p Z 0.031) and renal insufficiency (28.57% vs. 11.54%; p Z 0.049). In contrast, fewer people !65 years old had S. enterica serovar D bacteremia (53.06% vs. 75.00%; p Z 0.036). In patients with ciprofloxacin-nonsusceptible bacteremia, there were more S. enterica serovar C 1 and S. enterica serovar C 2 isolates than in the ciprofloxacinsusceptible groups (C 1 , 25.00% vs. 3.23%, p Z 0.049; C 2 , 37.50% vs. 4.30%, p Z 0.010). Comorbidities such as renal insufficiency (50.00% vs. 17.20%, p Z 0.047) and immunosuppressive agent usage (25.00% vs. 3.23%; p Z 0.049) were more common in the ciprofloxacin-resistant bacteremia group.
All variables with a p value of 0.05 in the univariate analysis were considered for inclusion in the logistic regression model for the multivariate analysis. Table 2 shows the multivariate analysis of risk factors in patients !65 years old and ciprofloxacin-nonsusceptible strains among adult patients with S. enterica bacteremia determined through the logistic regression analysis. Multivariate analysis revealed that the independent factor associated with !65-year-old elderly patients included renal insufficiency (OR 3.774; p Z 0.020) and heart disease (OR 2.922; p Z 0.027). The independent risk factors for ciprofloxacinnonsusceptible strains included S. enterica serovar C 2 (OR 28.430; p Z 0.032), renal insufficiency (OR 13.927; p Z 0.032), and immunosuppression agent usage (OR 60.082; p Z 0.006). Table 3 shows the clinical characteristics of patients, serogroups, QRDR of all subunits for the DNA gyrase (gyrA) gene and topoisomerase IV (parC ) gene, and MICs among the ciprofloxacin-nonsusceptible Salmonella bacteremia. The most common serogroup in ciprofloxacin-nonsusceptible Salmonella isolates was S. enterica serovar C (62.50%, 5/8), including two S. enterica serovar C 1 and three S. enterica serovar C 2 isolates.
Isolates with the gyrA mutation comprised 87.50% (7/ 8), while 62.50% (5/8) of the isolates had the parC mutation, but none had gyrB or parE mutations. The gyrA mutations were manifested as Ser83Phe, Asp87Asn, and Ser83Tyr. The parC mutations were manifested as Thr57Ser and Ser80Ile. The two isolates of S. enterica serovar C 1 with Ser83Phe/Asp87Asn gyrA mutation and Thr57Ser/Ser80Ile parC mutations exhibited high-level resistance to ciprofloxacin (MIC ! 4 mg/L). The other isolates harboring either the gyrA mutation or parC mutation gene presented low-level resistance to ciprofloxacin (MIC Z 2 mg/L).
The similarity of PFGE patterns in eight ciprofloxacinnonsusceptible Salmonella blood isolates is presented in Figure 1 . Isolates No.5 and No.6 of S. enterica serovar C 1 were considered to belong to the same cluster. Isolates No.7 and No.8 of S. enterica serovar B were considered to belong to the same cluster when their similarity coefficient reached 85%.
We also attempted to match our study participants with the simple scoring algorithm designed by Chen et al 22 to predict vascular infections with nontyphoidal Salmonella bacteremia in our study. We found a high sensitivity [100%, 5/(5þ0)] and an acceptable specificity [47.44%, 37/ (41þ37)] of vascular infections in patients.
Discussion
This study had two main objectives. The first objective was to elucidate the prevalence of S. enterica serogroups. The second objective was to investigate the difference between patients with Salmonella bacteremia in those <65 and !65 years old and in those afflicted with ciprofloxacinsusceptible strains versus those with ciprofloxacinnonsusceptible strains.
The serogroup distribution of Salmonella bacteremia may vary in different geographical localities. In our study, the most common serogroup of Salmonella bacteremia was S. enterica serovar D (64.36%, 65/101). The second most common serogroup was S. enterica serovar B (21.78%, 22/ 101), followed by S. enterica serovar C 2 (6.93%, 7/101), S. enterica serovar C 1 (4.95%, 5/101), and S. enterica serovar Typhi (1.98%, 2/101). These results corroborate those of Lin et al, 4 who analyzed patients from northern Taiwan in 2010e2012 and found that the most common Salmonella serogroup was S. enterica serovar D (68.8%), followed by S. enterica serovar B (23.4%), S. enterica serovar C 2 (6.3%), and S. enterica serovar C 1 (1.6%).
Our findings had some differences from previous reports. Parry et al 2 revealed that serogroups causing bacteremia included S. Enteritidis (47.6%) and S. Typhimurium (14.3%) for patients from Liverpool, UK. Li et al 6 demonstrated that the serogroups of nontyphoidal Salmonella isolates included S. enterica serovar B (40.2%), S. enterica serovar D (30.9%), S. enterica serovar C (26.5%), and S. enterica serovar E (1.5%) in patients with malignancy from southern Taiwan. Yen et al 8 showed that infections in 31 patients (39.24%) were due to S. enterica serovar D. Infections were due to S. enterica serovar B in 24 patients (30.38%) and S. enterica serovar C in 22 patients (27.85%) from northern Taiwan in 2001e2003.
Interestingly, Zaidenstein et al 23 found that males !60 years of age were more likely to have bacteremia than females of the same age. They also showed that S. enterica serovar Enteritidis had the highest incidence in patients' !60 years old. Some studies suggested that the risk factors were associated with underlying diseases, such as diabetes mellitus, human immunodeficiency virus infection, and solid tumor. 8, 24 However, we found that heart disease and renal failure were more common in those with Salmonella bacteremia who were !65 years old. The discrepancies may vary between different geographical localities or different study periods. We suggest that separate outbreak investigations should be performed in each hospital setting, and infection control strategies need to be developed to limit the spread of Salmonella infection. The nonsusceptible rate of ciprofloxacin resistance in our study was 7.92% (8/101). In contrast, Wang et al 25 showed that the overall rate of ciprofloxacin resistance among their S. Choleraesuis isolates was 59%, and the annual rate increased with time from 0% prior to 2000 to 80% in 1996e2004 in northern Taiwan. Liao et al 26 found that there was a significant reduction in the incidence of S. Choleraesuis bacteremia during 2005e2006 since its peak in 2004 and that the incidence remained low at both institutions during 2006e2011 in northern Taiwan. In contrast, the percentage of S. Choleraesuis isolates with ciprofloxacin resistance was approximately 80% during 2001e2004 and 100% during 2006e2011. 26 Chiou et al. revealed that different ciprofloxacin resistance rates of Salmonella enterica serovar Typhi isolates from Bangladesh and Taiwan. Among the isolates from Bangladesh, 39.5 % (15/38) were resistant to ciprofloxacin, and from Taiwan, 0% (0/36) were resistant. We presented that the two Salmonella enterica serovar Typhi isolates were susceptible to ciprofloxacin in this study. Our results were in accord with that reported previously in Taiwan. 27 However, Lee et al. presented that there were two Salmonella enterica serovar Typhi isolates with complete resistance to ciprofloxacin (MIC >32 mg/L) from Taiwan in 2011. The two isolates were from one patient who had recently travelled to India. 28 We also found that the clinical characteristics of patients harboring ciprofloxacin-nonsusceptible isolates were significantly different from those harboring ciprofloxacinsusceptible isolates. Patients with ciprofloxacinnonsusceptible isolates were more likely to have renal insufficiency comorbidity and immunosuppressive agent usage. Chen et al 7 reported the highest risk in the elderly from southern Taiwan with age-related disorders and younger patients receiving immunosuppressive therapy for their underlying diseases.
In this study, the eight ciprofloxacin-nonsusceptible isolates were associated with mutations gyrA and parC to ciprofloxacin within QRDRs in Salmonella. 87.50% (7/8) of the isolates had gyrA mutation and 62.50% (5/8) of the isolates had parC mutation, but none had gyrB and parE mutations. In contrast, in Malaysia, Karunakaran et al 29 detected the qnrS gene in 17/23 (73.91%), and single gyrA mutations were detected in 6/23 [26.09%; Asp87Tyr (n Z 3), Asp87Asn (n Z 2), and Ser83Phe (n Z 1)]. A parC (Thr57Ser) mutation was detected in 13/23 (56.52%) of the isolates coexisting with either a qnrS gene or a gyrA mutation. Although the detected rate of gyrA mutation was different in our report, the coexisting gyrA and parC mutations presenting high-level ciprofloxacin resistance had the same results. A first-step mutation reduced the susceptibility of DNA gyrase to a low level, and additional mutations in gyrA or mutations in parC could further augment resistance. The parC alterations played a complementary role in the development of higher-level fluoroquinolone-resistance. 14, 29 One limitation of this study is that it was conducted in a single medical center and the results may not be applicable to other hospitals. Another limitation is that the isolates were only identified as serogroups, such as crude S. enterica serovar B, S. enterica serovar C 1 , S. enterica serovar C 2 , S. enterica serovar D, or S. Typhi by the conventional biochemical tests and "O" Group typing in the microbiological laboratory.
In conclusion, this study demonstrates that among adult patients with Salmonella bacteremia, the risk factors of !65 year-old elderly patients included renal insufficiency and heart disease. The risk factors of ciprofloxacinnonsusceptible strains included S. enterica serovar C 2 , renal insufficiency, and immunosuppression agent usage. Furthermore, the eight ciprofloxacin-nonsusceptible isolates carried gyrA and parC mutations, whereas gyrB and parE mutations were not found. The isolates with coexisting Ser83Phe/Asp87Asn gyrA mutation and Thr57Ser/Ser80Ile parC mutation genes exhibited high-level resistance to ciprofloxacin (MIC ! 4 mg/L). Resistance caused by gyrA and parC mutations among ciprofloxacin-nonsusceptible isolates poses a major concern.
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